Canva integrates Google's Veo 3 to enable video clips with sound
Live Events
Canva has launched a new 'Create a Video Clip' feature backed by Google 's Veo 3 video generation model. In an announcement on its website, the company said users can now create eight-second video clips with sound using text or voice prompts.This feature is available to users on paid plans (Pro, Teams, and Enterprise), as well as Canva for nonprofit users . It is also accessible to paid subscribers of Leonardo.Ai, a generative AI startup acquired by Canva in 2024.As of now, users are limited to generating five videos per month, but the company has stated that access will be gradually expanded over time.Veo 3 was released by Google last month at the I/O 2025 developer conference , as an upgrade to its predecessor, Veo 2. While Veo 2 could generate visuals, it lacked sound. Veo 3, on the other hand, can synchronise lip movements with dialogue, simulate real-world physics, and interpret complex commands.To get started, users can go to Canva AI from the homepage or sidebar and select the 'Create a Video Clip' option. Then, they need to enter a prompt that details what is needed in the video. Thereafter, a video is generated.If further refinement or fine-tuning is needed, Canva's video editor can customize the clip as required.In addition to this feature, Canva also revealed plans to acquire MagicBrief, an Australian creative intelligence startup founded in 2022.'Their AI-powered platform makes it easier for marketers to unlock, understand, and respond to the content strategies, formats, and messages that perform best,' the company said.
Try Our AI Features
Explore what Daily8 AI can do for you:
Comments
No comments yet...
Related Articles
Economic Times
4 hours ago
- Economic Times
Cryptocurrency Live News & Updates : Bitcoin Remains Stable Amid Middle East Tensions
20 Jun 2025 | 02:05:11 AM IST Despite rising geopolitical tensions, Bitcoin's price has remained stable, with NoOnes CEO Ray Youssef suggesting it now behaves more like a tech stock than a hedge asset. Recent developments in the cryptocurrency market reveal a complex landscape. Bitcoin's price has remained around $105,000 despite escalating tensions in the Middle East, with CEO Ray Youssef of NoOnes noting that Bitcoin is increasingly acting like a tech stock rather than a hedge asset. Meanwhile, Sei Network's token surged over 13% after being selected as a candidate blockchain for Wyoming's upcoming WYST stablecoin, highlighting growing institutional interest in stablecoins. Ethereum is also gaining traction, with strategic reserves reaching 1% of its total supply, driven by corporate adoption. Notably, major holders like the Ethereum Foundation and SharpLink are leading this trend. On the other hand, Hedera Hashgraph's HBAR token has faced challenges, dropping significantly and forming a death cross pattern, despite the launch of AUDD, the first Australian dollar stablecoin on its network. This juxtaposition of stability in Bitcoin and Ethereum against the backdrop of HBAR's struggles illustrates the diverse dynamics at play in the cryptocurrency market. Show more
&w=3840&q=100)
Business Standard
5 hours ago
- Business Standard
Tesla joins Austin's self-driving race with launch of Robotaxi service
Austin is known for live music, Texas' premier public university and being home to tech companies. It is also becoming a laboratory for autonomous vehicles. Driverless Waymo taxis, owned by Google's parent company, regularly drop off diners at Austin's famous barbecue joints. Box-shaped, four-wheeled robots operated by Avride, a start-up working with Uber Eats, deliver Thai takeout to customers downtown. Zoox, owned by Amazon, and Volkswagen are separately testing autonomous taxis here. Tesla, the electric car company based in Austin, recently joined the party, rolling out self-driving Model Ys ahead of a taxi service that is expected to begin offering rides as soon as Sunday. The vehicles, which the company calls Robotaxis, are part of an audacious effort by Elon Musk, Tesla's chief executive, to leap ahead of Waymo, which dominates a nascent business that someday could be worth tens of billions of dollars and perhaps much more. But the busy streets of Austin show that Tesla will face significant competition and other challenges. It will have to engage in painstaking experimentation to perfect its technology, which some autonomous-driving experts have criticised for having fewer safeguards than those operated by Waymo and other companies. Also, Tesla is starting from behind. Waymo has been driving paying passengers for years in Phoenix, San Francisco and Los Angeles, and started its commercial service in Austin in March in partnership with Uber. Waymo said on Wednesday that it was applying for a permit from New York City to offer rides with a person behind the wheel. A change in state law would be required for fully autonomous rides. A small fleet of Tesla Robotaxis will begin carrying passengers in Austin on June 22, Musk said on X last week but added the company may delay the start of the service. But analysts expect the cars will be available only to company employees or invited guests. The service will probably not be available to the general public for several months, analysts said. Tesla is adapting its most advanced driver assistance software, already offered as an option on the cars it sells, to operate without human intervention. If this approach works, the company could quickly roll out driverless taxis around the world. Musk has said a software update could allow hundreds of thousands or even millions of existing Teslas to operate as autonomous taxis, making cheap driverless rides ubiquitous. But the approach Tesla is taking is unusual. Waymo and other companies working to offer self-driving taxi services have been developing their technologies for years, painstakingly mapping streets and training their software to avoid hitting pedestrians, cyclists, garbage trucks, fire engines and all manner of other things found on public roads. 'FSD is an immature system,' said Matthew Wansley, a professor at Cardozo School of Law in New York, referring to what Tesla calls its Full Self-Driving (Supervised) software. Tesla did not respond to a request for comment. Another challenge for Tesla is that its self-driving system is under investigation by federal officials. The National Highway Traffic Safety Administration is looking into whether Tesla's technology was responsible for crashes in conditions where the road was obscured by fog, dust, bright light or darkness. One crash led to the death of a pedestrian.
Economic Times
7 hours ago
- Economic Times
Rx Name Unethical Practitioners: A medical thriller unfolds in India
Don't hide them behind stethos In an episode that could rival a streaming medical thriller, Department of Pharmaceuticals' (DoP) Apex Committee for Pharma Marketing Practices, under the ministry of chemicals and fertilisers, has found that AbbVie Healthcare India, a subsidiary of the US-based AbbVie Inc, had sponsored international trips for 30 doctors by spending nearly ₹1.91 cr in breach of Uniform Code for Pharmaceutical Marketing Practices (UCPMP) 2024. The trips were to Paris and Monaco - for an 'anti-ageing conference'. The twist? DoP refuses to reveal the names of these doctors, claiming that it would serve 'no public interest'. Seriously? Under Section 8(1)(j) of RTI Act, personal information can be withheld unless it relates to public activity, or involves a larger public interest. The Supreme Court in 'CBSE v. Aditya Bandopadhyay' (2011) clarified that public interest trumps privacy when the matter involves ethics, misuse of public trust or potential illegality. Exposing medical professionals breaching ethical codes is as public interest-worthy as things can get. These were corporate-sponsored trips in violation of Medical Council of India (MCI) Code of Ethics, now incorporated under National Medical Commission (NMC). It could also be a tax issue. In 'Apex Laboratories Pvt. Ltd. v. CIT' (2022), Supreme Court held that pharma companies can't claim expenses on such freebies as business deductions under Section 37(1) of I-T Act. Any expenditure prohibited by law, or contrary to public policy, can't be deemed a legitimate business expense. Finance Bill 2022 reinforced this, barring deductions for any expense in violation of MCI Code or Clause 7.2 of the UCPMP (Uniform Code for Pharmaceutical Marketing Practices). Under Section 28(iv), any non-cash benefit or perk arising from the exercise of a profession is taxable as 'profits and gains from business or profession'. So, doctors cannot claim these as business expenses, write them off or hide them behind a stethoscope. These are professional receipts, and I-T department expects them to be are these freebies valued by the recipient? Where value is ascertainable, the law mandates it be used. For goods - say, a smartphone - use the fair market value. For services like travel or hotel stays, the actual cost to provider - in this case, AbbVie - must be included. Doctors are expected to report these benefits and maintain documentary evidence, such as brochures, invoices, travel itineraries, etc. There are penalties for wilful concealment.I-T department's investigation wing can legally requisition information from DoP, the sponsoring pharma company - AbbVie, here - and even travel agencies that arranged these foreign trips. If AbbVie failed to report these expenses under Section 285BA (statement of financial transactions) of I-T Act, it could constitute non-reporting of high-value data in hand, under Section 147 (reassessment), if any income (like value of these freebies) has escaped assessment, the assessing officer can reopen past returns. Under Section 69/69B, any unexplained income or expenditure can be added to the doctor's taxable income. Non-disclosure triggers penalties under Section 270A, interest under Sections 234B and 234C, and in cases of wilful concealment, prosecution under Section as a US multinational, could also fall under Foreign Corrupt Practices Act (FCPA). Under FCPA, doctors at public hospitals abroad - in this case, in India - are treated as foreign officials. Giving 'anything of value' - from per diems and conference sponsorships, to charitable donations - with a corrupt intent can trigger civil and criminal penalties in the US. Several global pharma companies have already faced FCPA enforcement for sponsoring foreign trips, or donating to charities run by government we have here is actually a systemic failure to enforce transparency in an area that affects public health, tax revenue and professional integrity. By refusing to name the doctors, DoP is enabling opacity, shielding violators and undermining the credibility of India's regulatory it sends a dangerous signal. The refusal to reveal names is not about privacy. It's about protecting privilege. And when privilege leads to tax evasion and ethical violations, silence becomes a public trust deficit. In this case, what happened in Paris and Monaco shouldn't stay in Paris and Monaco. (Disclaimer: The opinions expressed in this column are that of the writer. The facts and opinions expressed here do not reflect the views of Elevate your knowledge and leadership skills at a cost cheaper than your daily tea. Why Infy's Parekh takes home more than TCS' CEO despite being smaller Central bankers print currency for all, but why do they chase gold? Worrying cracks hiding behind MG Motor's own 'house of Windsor' Why failed small businessmen die by suicide when those behind big blow-ups bounce back? Stock Radar: Ascending Triangle pattern breakout makes Mphasis an attractive buy; stock up over 30% from April lows Buy, Sell or Hold: BSE doubles from March lows, but brokerages turn cautious after SEBI's expiry day directive These mid-cap stocks with 'Strong Buy' & 'Buy' recos can rally over 25%, according to analysts F&O Radar| Deploy Bear Put Spread in Nifty for gains from volatility, negative stance
